Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma
Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both,…
Oncology
-
-
Intensity Therapeutics stock up nearly 400% on solid tumour data
Intensity Therapeutics’ stock has risen nearly 400% after its oncology candidate showed high overall survival (OS) and disease control. In…
-
Proactive strategy needed to ensure Project Optimus compliance
Sponsors should ensure dose optimisation is a part of early trial planning for oncology trials as the US Food and…
-
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous…
-
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability
MSD and Eisai’s combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) has shown a durable benefit of five years in a…
-
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
-
Sanofi’s €320m bet pays off as radiopharmaceutical shows benefit in GEP-NETs
Sanofi and Orana Med’s radiopharmaceutical candidate has met all its primary endpoints in a Phase II trial, meaning the former’s…
-
OS endpoint focus will realign industry to “ultimate goal”
In oncology trials, overall survival (OS) has always been the gold standard endpoint, with all biotech and pharma companies developing…
-
BMS to speak with regulators on mid-stage multiple myeloma success
Bristol Myers Squibb’s (BMS’s) investigational cereblon E3 ligase modulator iberdomide has shown promise in a mid-stage endpoint of a multiple…
-
Genentech to file for oral SERD approval on Phase III breast cancer win
Genentech will be heading to regulators after the Phase III success of its oral selective oestrogen receptor degrader (SERD) and…
